Adrenergic beta agonists and anticholinergics in obstructive lung diseases

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 10, Issue 1, 1997, Pages 75-83

  Lemarié, Etienne ^a   Diot, Patrice ^a  

^a CHU BRETONNEAU   (France)

Author keywords

anticholinergic; beta agonist; obstructive lung disease

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

AEROSOL; AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRUG INDUCED DISEASE; DRUG MECHANISM; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; METERED DOSE INHALER; VAGUS NERVE;

EID: 0030888754     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.1997.10.75     Document Type: Conference Paper

References (39)

1. American Thoracic Society. 1962. Chronic bronchitis, asthma, and pulmonary emphysema: A statement by the Committee on diagnostic standards for nontuberculous respiratory diseases. Am. Rev. Respir. Dis. 85:762-768.
2. American Thoracic Society. 1995. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 152:S77-S120.
3. Siafakas, N.M., P. Vermeire, N.B. Pride, P. Paoletti, J. Gibson, P. Howard, J.C. Yernault, M. Decramer, T. Higenbottam, D.S. Postma, and J. Rees. 1995. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 8:1398-1420.
4. Kim, C.S., G.G. Lewards, and M.S. Sackner. 1988. Measurement of total lung aerosol deposition as an index of lung abnormality. J. Appl. Physiol. 64:1527-1536.
5. Anderson, P.J., J.D. Wilson, and F.C. Hiller. 1990. Respiratory tract deposition of ultrafine particles in subjects with obstructive or restrictive lung diseases. Chest 97:1115-1120.
6. Itoh, H., Y. Ishii, H. Maeda, G. Todo, K. Torizuka, and G.C. Smaldone. 1981. Clinical observations of aerosol deposition in patients with airways obstruction. Chest 80:837-839.
7. Sweeney, T.D., W.A. Skornik, J.D. Brain, V. Hatch, and J.J. Godleski. 1995. Chronic bronchitis alters the pattern of aerosol deposition in lung. Am. J. Respir. Crit. Care Med. 151:482-488.
8. Gross, N.J. and M.S. Skorodin. 1984. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 311:421-425.
9. Gross, N.J. and M.S. Skorodin. 1984. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 311:421-425.
10. Barnes, P.J. 1986. Neural control of human airways in health and disease. Am. Rev. Respir. Dis. 134:1289-1314.
11. Hensley, M.J., C.F. O'Cain, E.R. MacFadden, and R.H. Ingram. 1978. Distribution of bronchodilation in normal subjects: beta agonist versus atropine. J. Appl. Physiol. Respirat. Environ. Exercise. Physiol. 45:778-782.
12. Barnes, P.J., C.B. Basbaum, J.A. Nadel, and J.M. Roberts. 1982. Localization of beta-adrenoreceptors in mammalian lung by light microscopic autoradiography. Nature 299:444-447.
13. Tashkin, D.P., K. Ashutosh, and E.R. Bleecker. 1986. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: A 90-day multicenter study. Am. J. Med. 81(5A):81-90.
14. Francis, R.A., M.L. Thomson, D. Pavia, and R.B. Douglas. 1977. Ipratropium bromide: Bronchociliary clearance rate and airway resistance in normal subjects. Br. J. Dis. Chest 71:173-178.
15. Pavia, D., J.R.M. Bateman, N.F. Sheahan, and S.W. Clarke. 1980. Clearance of lung secretions in patients with chronic bronchitis: Effect of terbutaline and ipratropium bromide aerosols. Eur. Respir. Dis. 61:245-253.
16. Braun, S.R., W.N. McKenzie, C. Copelan, L. Knight, and M. Ellersieck. 1989. A comparison of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch. Int. Med. 149:544-547.
17. Smaldone, G.C., W.M. Foster, T.G. O'Riordan, M.S. Messina, R.J. Perry, and E.G. Langenback. 1993. Regional impairment of mucociliary clearance in chronic obstructive pulmonary diseases. Chest 103:1390-1396.
18. Foster, W.M., E.H. Bergofsky, D.E. Bohning, M. Lippman, and R.E. Albert. 1976. Effects of adrenergic agents and their mode of action on mucociliary clearance in man. J. Appl. Physiol. 41:146-152.
19. Perry, R.J. and G.C. Smaldone. 1990. Effect of bronchodilators on mucociliary clearance in normal adults. 1990. J. Aerosol Med. 3:187-196.
20. Gross N. and Z. Bankwala. 1987. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 136:1091-1094.
21. Viegas, C.A., A. Ferrer, J.M. Montserrat, J.A. Barbera, J. Roca, and R. Rodriguez-Roisin. 1996. Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. Chest 110:71-77.
22. Lipworth, B.J., D.M. Newnham, R.A. Clark, D.P. Dhillon, J.H. Winter, and D.G. McDevitt. 1995. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 50:54-61.
23. Kalra, L. and M. Bone. 1988. The effect of nebulized bronchodilator therapy on intraocular pressure in patients with glaucoma. Chest 93:739-741.
24. Hansen, N.C.G. 1989. Terbutaline as powder inhalation from Bricanyl Turbuhaler compared to terbutaline as nebulizer solution in severe chronic airways obstruction. Eur. Respir. J. 2:716-720.
25. Dolovich, M., M. Vanzieleghem, K.G. Hidinger, and M. Newhouse. 1988. Influence of inspiratory flow rate on the response to terbutaline sulphate inhaled via the Turbuhaler. Am. Rev. Rspir. Dis. 137(part 2):433.
26. Easton, P.A., C. Jadue, S. Dinghra, and N.R. Anthonisen. 1986. A comparison of the bronchodilating effect of beta2-adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide) given by aerosol alone or in sequence. N Engl. J. Med. 315:735-739.
27. Karpel, J.P. 1991. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 99:871-876.
28. Anthonisen, N.R. 1995. Anticholinergics in obstructive lung disease. Eur. Respir. Rev. 31:347-347.
29. Ikeda, A., K. Nishimura, H. Koyama, and T. Izumi. 1995. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD. Chest 107:401-405.
30. Combivent Inhalation Aerosol Study Group. 1994. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 105:1411-1419.
31. Hay, J.G., P. Stone, J. Carter, S. Church, A. Eyre-Brook, M.G. Pearson, A.A. Woodcock, and P.M.A. Calverley. 1992. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur. Respir. J. 5:659-664.
32. Blosser, S.A., S.L. Maxwell, M.K. Reeves-Hoche, A.R. Localio, and C.W. Zwillich. 1995. Is an anticholinergic agent superior to a beta-agonist in improving dyspnea and exercise limitation in COPD? Chest 108:730-735.
33. Karpel, J.P., J. Pesin, D. Greenberg, and E. Gentry. 1990. A comparison of ipratropium bromide and metaproterenol sulphate in acute exacerbations of COPD. Chest 98:835-839.
34. Rebuck, A.S., K.R. Chapman, R. Abboud, P.D. Pare, H. Kreisman, N. Wolkove, and F. Vickerson. 1987. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airway disease in the emergency room. Am. J. Med. 92:59-64.
35. Moayyedi, P., J. Congleton, R.L. Page, S.B. Pearson, and M.F. Muers. 1995. Comparison of nebulized salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 50:834-837.
36. Rennard, S.I., C.W. Serby, M. Ghafouri, P.A. Johnson, and M. Friedman. 1996. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. Chest 110:62-70.
37. 1. JAMA 272:1497-1505.
38. Wanner, A. and M.R. Sears. 1995. Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? Am. J. Respir. Crit. Care Med. 151:597-599.
39. Ulrik, C.S. 1995. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: A single centre randomised, double blind, placebo controlled, crossover study. Thorax 50:750-754.